Deregulation of apoptosis in acute myeloid leukemia

Haematologica

Volumn 92, Issue 1, 2007, Pages 81-94

  Testa, Ugo ^a   Riccioni, Roberta ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Acute myeloid leukemia; Apoptosis; Deregulation

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; APOPTOSOME; CASPASE INHIBITOR; DEATH RECEPTOR; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; FLICE INHIBITORY PROTEIN; HGS ETR1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG HALF LIFE; DRUG TOLERABILITY; HEMATOPOIETIC CELL; HOMEOSTASIS; HUMAN; IN VIVO STUDY; LEUKEMIA CELL; NONHUMAN; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT;

APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LIGANDS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 33846903320     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10279     Document Type: Article

References (122)

1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukaemia. Blood 2005;106:1154-63.
2. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005;23:6285-95.
3. Hanahn P, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
4. Reya T, Morrison SJ, Calrke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
5. Lapidot T. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994;367:645-8.
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 1997;3:730-7.
7. Alcalay M, Orleth A, Sebastiani C, Meani N, Chiaradonna F, Casciani C, et al. Common themes in the pathogenesis of acute myeloid leukemia. Oncogene 2001;20:5680-94.
8. Pearce DJ, Taussing D, Zibara K, Smith LL, Lister TA, Bonnet D. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006;107:1166-73.
9. Taussing DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. 2005;106:4086-92.
10. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci USA 1996;95:11863-8.
11. Britos-Bray M, Ramirez M, Cao W, Wang X, Liu PP, Civin CI, Friedman AD. CBF-SMMHC, expressed in M4eo acute myeloid leukaemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents. Blood 1998;92:4344-52.
12. Pandolfi PP. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukaemia. Hum Mol Genet 2001;10:769-75.
13. Adler HT, Chinery R, Wu DY, Sussick SJ, Payne JM, Fornace AJ, et al. Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INH proteins. Mol Cell Biol 1999;19:7050-60.
14. Testa U, Grignani F, Samoggia P, Zanetti C, Riccioni R, Lo Coco F, et al. The PML/RAR fusion protein inhibits tumor necrosis factor-α-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. J Clin Invest 1998;101:2278-89.
15. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005;90:612-24.
16. Falini B, Mecucci C, Tiacci F, Alacalay M, Lo-Coco F, Pelicci PG, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352:254-66.
17. Verhaak RG, Goudswaard CS, Lowenberg B, Valk PJ. Mutations in nucleophosmin (NPM1) in acute myeloid leukaemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favourable prognostic significance. Blood 2005;106:3747-54.
18. Lambert B, Buckle M. Characterization of the interface between nucleophosmin (NPM) and p53: potential role in p53 stabilization. FEBS Lett 2006;6580:345-50.
19. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nature Rev Cancer 2006;6:493-505.
20. Colombo E, Bonetti P, Falini B, Pelicci PG. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 2005;25:8874-86.
21. Stirewalt DL, Radich JP. The role of FLT3 in hemopoietic malignancies. Nat Rev Cancer 2003;3:650-65.
22. Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood 2003;102:2969-75.
23. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005;105:1759-67.
24. Kohl TM, Schnittger S, Ellwart JW. Kit exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005;105: 3319-21.
25. Corbacioglu S, Kilic M, Westhoff MA, Reinhardt D, Fulda S, Debatin KM. Newly identified c-kit receptor tyrosine kinase ITD in childhood AML induces ligand independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006;108:3504-13.
26. Schnittger S, Kohl TM, Haferlach T, Kern W Hiddemann W, Spiekemann K, et al. KIT-816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1790-9.
27. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kolitz JE, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukaemia with inv(16) and t(8;21): a cancer and leukaemia group B study. J Clin Oncol 2006;24:3904-11.
28. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway. A rational mechanism-based treatment for hematologic malignancies¿ Blood 2000;96:1665-9.
29. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107:3847-53.
30. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood; in press 2006.
31. Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastric leukaemia. Immunity 1998;9: 47-57.
32. Bullinger L, Valk PJM. Gene expression profiling in acute myeloid leukaemia. J Clin Oncol 2005;23:6296-305.
33. Valk PJM, Verhaak RGW, Lowenberg B, Ruud D. Prognostically useful gene-expression profiles in acute myeloid leukaemia. N Engl J Med 2004;350:1617-28.
34. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, et al. Use of gene-expression profiling to identify prognostic subclasses in adult myeloid leukaemia. N Engl J Med 2004;350:1605-16.
35. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R. et al. Gene expression profiling of adult acute myeloid leukaemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006;108:685-96.
36. Min YH, Cheong JW, Kim JY. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukaemia. Cancer Res 2004;64:5225-31.
37. Martelli AM, Nyakjern M, Bortul R, Tarzani PL, Evalengelisti C, Cocco L. Phosphaphoinositide 3-kinase/Aky signaling pathway and its therapeutical impklications for human acute myeloid leucemia. Leukemia 2006;20:911-28.
38. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leucemia cell requires PI3 kinase activation. Blood 2003; 102:972-80.
39. Kim SC, Hahn JS, Min YH. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PACI. Blood 1999; 93:3893-9.
40. Milella M, Kornblau SM, Estrov Z. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-9.
41. Kornblau SM, Womble M, Qiu YH, Jackson E, Chen W, Konopleva M, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006;108:2358-65.
42. Bazzoni F, Butler B. The tumor necrosis factor ligand and receptor families N Engl J Med 1996;334:1717-25.
43. Ogasarawa J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in the mice. Nature 1993; 364: 806-9.
44. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
45. Kelley S, Harris L, Xie D, DeForge L, Totpal K, Bussiere J. et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization on in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-8.
46. Yagita H, Takeda K, Hayakawa Y, Smyth M, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004;95: 777-83.
47. Pulac L, Kanakara P, Humphreys R, Alderson R, Dobson C, Salcedo T, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumor types in vitro and in vivo. Br J Cancer 2005;92:1430-41.
48. Le L. Phase I study of a fully human monoclonal antibody to the Tumor Necrosis Factor-Related Apoptosis-inducing Ligand Death Receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma. AmericaN Society of Clinical Oncology Annual Meeting. 2004.
49. Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dorken B, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity. Leukemia 2001;15:921-8.
50. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005;90:612-24.
51. Cappellini A, Mantovani I, Tazzari PL, Grafone T, Martinelli G, Cocco L, Martelli AM. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukemia blasts. Int J Mol Med 2005;16:1041-8.
52. Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreef M, et al. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 2003; 17:2122-9.
53. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leucemia cells. Nat Med 2005;11:77-84.
54. Hasegawa H, Yamada Y, Masuda M, Takasu N, Kamihira S. Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood 2006;107:679-88.
55. Szegezdi E, Cahill S, Meyer M, O'Dwyer M, Samali A. TRAIL sensitization by arsenic trioxide is caspases-8 dependent and involves modulation of death receptor component and Akt. Br J Cancer 2006;94:398-406.
56. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001;7: 680-6.
57. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF- B. Oncogene 2003;22: 3842-52.
58. Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 2005;65:7888-95.
59. Tourneur L, Buzyn A, Chiocchia G. FADD adaptor in cancer. Med Immunol 2005;4:1-15.
60. Alappat EC, Feig C, Boyerinas B, Volkland J, Samuels M, Murmann AE, et al. Phosphorylation of FADD at serine 194 by CKI regulates its nonapoptotic activities. Mol Cell 2005;19:321-32.
61. Tourneur L, Delluc S, Levy V, Valensi F, Radford-Weiss I, Legrand O, et al. Absence or low expression of Fas-associated protein with death domain in acute myeloid leukaemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res 2004;64:8101-8.
62. Iijima N, Mioyamura K, Itou T, Tanimoto M, Sobue R, Saito H. Functional expression of Fas (CD95) in acute myeloid leukaemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood 1997;90: 4901-9.
63. Lewis NR, Pallis M, Russell NH. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukaemia. Exp Hematol 2000;28:535-42.
64. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sesitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspases-8 activation and apoptosis. Cancer Res 2001;61:1645-51.
65. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 2006;6:159-204.
66. Wallach D. Placing death under control Nature 1997;388:123-6.
67. Tschopp J, Irmler M, Thome M. Inhibition of Fas death signals by FLIPs. Curr Opin Immunol 1998;10:552-8.
68. Gloks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN. c-FLIPR, a new regulator of death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 2005;280:14507-13.
69. Sharp DA, Lawrence DA, Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspases-8 activation and apoptosis. J Biol Chem 2005;280:19401-9.
70. Micheau O, Lens S, Gaide O, Alevidopoulos K and Tschopp J. NF-κB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21:5299-305.
71. Valnet-Rabier MB, Chalier B, Thiebault S, Angonin R, Margueritte G, Moyugin C, et al. c-FLIP protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol 2005;128:767-73.
72. Krueger A, Fas SC, Giaisi M, Bleumink M, Merling A, Stumpf C, et al. HTLV-1 tax protects against CD95-mediated apoptosis by induction of the cellular FLIC-inhibitory protein (c-FLIP). Blood 2006;107:3933-9.
73. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Belmont J, et al. The synthetic CDDO induces caspase-dependent and independent apoptosis in acute myelogenous leukaemia. Cancer Res 2004;64:7927-33.
74. Kim Y, Suh N, Sporn MB, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2003;277: 22320-9.
75. Hyer ML, Croxton R, Krajewska M, Sporn MB, Cryns VL, Zapata JM, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 2005;65:4799-808.
76. Schimmer AD, Thomas MP, Hurren R, Gronda M, Pellecchia M, Pond GR, et al. Identification of small molecules that sensitize resistant tumor cells to tumor factor-family death receptors. Cancer Res 2006;66: 2367-75.
77. Ho Pk, Hawkins CJ. Mammalian initiator apoptotic caspases. FEBS J 2005; 272:5436-53.
78. Himeji D, Horiuchi T, Tsukamoto H, Hayashi K, Watanabe T, Harada M. Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. Blood 2002;99:4070-8.
79. Mohr A, Zwacka RM, Jarmy G, Buneker C, Schrezenmeier H, Dohner K, et al. Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene 2005; 24:2421-9.
80. Svingen PA, Karp JE, Kraiewski S, Mesner PW, Gore SD, Burke PJ, et al. Evaluation of Apaf-1 and procaspases-2, -3, -7, and -9 as potential prognostic markers in acute leukaemia Blood 2000;96:3922-31.
81. Tu S, McStay GP, Boucher LM, Mak T, Beere HM, Green DR. In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis. Nat Cell Biol 2006;8:72-7.
82. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004;304:843-6.
83. Janssens S, Tinel A, Lippens S, Tschopp J. PIDD mediates NF- B activation in response to DNA damage. Cell 2005;123: 1079-92.
84. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Harris D, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukaemia. Blood 1998;92:3090-7.
85. Holleman A, Den Boer M, Kazemeier KM, Beverloo HB, Von Bergh A, Janka-Schaub GE, et al. Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood lymphoblastic leukemia. Blood 2005;106:1817-23.
86. Tang J, Xie W, Yang X. Association of caspase-2 with the promyelocytic leukemia protein nuclear bodies. Cancer Biol Ther 2006;4: 645-9.
87. Scholz C, Wieder T, Starck L, Essmann F, Schulze-Osthoff K, Dorken B, et al. Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 2005; 24:1904-13.
88. Scholz C, Richter A, Lehmann M, Schulze-Osthoff K, Dorken B, Daniel PT. Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Oncogene 2005; 24:7031-42.
89. Fardel S, Thall PF, Kantarjian HM. Caspase 2 and caspases 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukaemia. Clin Cancer Res 2005;5:4041-7.
90. Campos L, Rouault JP, Sabido O. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81: 3091-6.
91. Andreef M, Konopleva M. Mechanisms of drug resistance in AML. Cancer Treat Res 2002;112: 237-62.
92. Banker DE, Radich J, Becker E. The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res 1998;4:3051-62.
93. Del Poeta G, Venditti A, Del Principe MI. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003;101:2125-31
94. Venditti A, Del Poeta G, Maurillo L, Buccisano F, Del Principe MI, Mazzone C, et al. Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. Haematologica 2004;89:934-9.
95. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other anti-apoptotic proteins. Blood 2000;95:3929-38
96. Van Stijn A, Van Der Pol MA, Kok A, Bontje PM, Roemen G, Beelen R, et al. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukaemia. Haematologica 2003; 88:497-508.
97. Paz-Priel I, Cai DH, Wang D, Kowalski J, Gombart AF, Koeffler HP, et al. CCAAT/Enhancer binding protein (C/EBPα) and C/EBPα myeloid oncoproteins induce Bcl-2 via interaction of their basic regions with nuclear factor-κB p50. Mol Cancer Res 2005;3:585-96.
98. Marcucci G, Stock W, Dai G. Phase I study of oblimersed sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 2005;23:3404-11.
99. Moore LO, Seiter K, Kolitz JE, Stock W, Yu R, Frankel SR. Phase 2 study of oblimersen sodium (G31\39; Bcl-2 antisense; Genasense) plus gentuzumab ozogamicin (Myelotarg) in elderly patients with relapsed acute myeloid leukemia (AML). Blood 2004;104:865.
100. Dai G, Chan KK, Liu S. Cellular uptake and intracellular levels of the Bcl-2 antisense G3139 in cultured cells and treated patients with acute myeloid leukemia. Clin Cancer Res 2005;11:2998-3008.
101. Kaufmann SH, Karp JE, Svingen PA, Kraiewski S, Burke PJ, Gore SD, Reed JC. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998;91:991-1000.
102. Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are overexpressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002;118:521-34.
103. Birkenkamp KU, Geugien M, Lemmink HH, Kruj W, Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukaemia blasts. Leukemia 2001;15:1923-31.
104. Minami Y, Yamamaoto K, Kiyoi H, Ueada R, Saito H, Naoe T. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood 2003;102:2969-75.
105. Bragintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl C, Elwart JW, et al. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-X(L). Blood 2005;105:3679-85.
106. Yang X, Liu L, Sternberg D, Tang L, Galinsky I, DeAngelo D, et al. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation a serine 112. Cancer Res 2005;65:7338-47.
107. Tamm I, Kornblau SM, Segal H, Krajewski S, Welsh K, Kitada S, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803.
108. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, et al. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003;102:4179-86.
109. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scolz F, et al. High expression levels of X-linked inhibitor of apoptosis protein and surviving correlate with poor overall survival in childhood de novo acute myeloid leukaemia. Clin Cancer Res 2004; 10:3737-44.
110. Tamm I, Richter S, Scholtz F, Schmelz K, Oltersdorf D, Karawajew L, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 2004;5:489-95.
111. Tamm I, Richter S, Oltersdiorf D, Creutzig U, Harbott J, Scholz F, et al. High expression levels of X-linked inhibitor of apoptosis protein and surviving correlate with poor overall survival in childhood de novo acute myeloid leukaemia. Clin Cancer Res 2004;10:3737-44.
112. Adida C, Recher C, Raffoux E. Expression and prognostic significance of IAP family genes in de novo acute myeloid leukemia. Br J Haematol 2000;111:196-203.
113. Gronda M, Brandwein J, Minden MD, Pond GR, Schub AC, Wells RA, et al. Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia. Apoptosis 2005;10:1285-94.
114. Mohr A, Zwacka RM, Debatin KM, Stahnke K. A novel method fort he combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ 2004;11:1153-4.
115. Meyer LH, Karawajew L, Schrappe M, Ludwig WD, Debatin KM, Stahnke K. Cytochrome c related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL. Blood 2006; in press.
116. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006;13:179-88.
117. Schimmer AD, Dalili S. Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. American Society Hematology 2005;215-9.
118. Carter BZ, Gronda M, Wang Z, Chun K, Reed JC, Schimmer AD. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukaemia cells. Blood 2005;105:4043-50.
119. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006;in press.
120. Jia L, Srinivasula S, Liu FT, Newland AC, Fernandes-Alnemri T, Alnemri ES, et al. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 2001;98:414-21.
121. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Hishii H, et al. Methylation silencing of the Apaf-1 gene in acute leukaemia. Mol Cancer Res 2005;3: 325-34.
122. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, et al. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 2003;22:451-5.